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Background: Higher intakes of flavonoids provide health benefits, however, the importance 46 
of each flavonoid class and which population groups may receive the greatest protection from 47 
higher flavonoid intake warrants further investigation. 48 
Objective: To explore the associations of flavonoid and flavonoid-rich wholefood intakes 49 
with all-cause mortality and the moderating effects of early mortality risk factors. 50 
Design: The study included 2 349 participants of The Blue Mountains Eye Study, with a 51 
mean±SD age at baseline of 64.7±9.2 years. We calculated flavonoid intake from baseline 52 
food frequency questionnaires using US Department of Agriculture food composition 53 
databases. Associations were examined using adjusted Cox proportional hazards models.  54 
Results: After 14 years of follow-up, 677 participants died. There was a flavonoid threshold 55 
effect with the greatest risk reduction seen between low and moderate intakes of total 56 
flavonoids, flavonoid classes and flavonoid-rich foods. Amongst the whole cohort, 57 
participants in the highest tertile of anthocyanidin intake had a significantly lower risk of all-58 
cause mortality [multivariable adjusted HR (95%CI): 0.76 (0.61, 0.94)] when compared to 59 
those in the lowest tertile. Amongst participants with at least one early mortality risk factor 60 
(smoking, high alcohol consumption, no regular exercise or obesity), risk of all-cause 61 
mortality was lower in those in the highest intake tertile for total flavonoids [adjusted HR: 62 
0.77 (0.59, 1.00)], flavan-3-ols [0.75 (0.58, 0.98)], anthocyanidins [0.70 (0.54, 0.92)], and 63 
proanthocyanidins [0.69 (0.52, 0.92)], compared to those in the lowest tertile. No similar 64 
associations were observed among those without any risk factors. Similarly, consumption of 65 




associated with a lower risk of all-cause mortality among participants with at least one risk 67 
factor, but not amongst other participants.   68 
Conclusion: Moderate to high intakes of flavonoids and certain flavonoid subclasses may 69 
provide health benefits, particularly for individuals with at least one early mortality risk 70 
factor. 71 
Keywords: Flavonoids, flavonoid-rich foods, all-cause mortality, prospective cohort 72 





Despite improvements seen in the past 25 years, dietary risk factors are still a major 75 
contributor to the burden of non-communicable diseases (NCDs) in Australia, with an 76 
estimated 19.7% of all deaths in 2015 attributable to dietary habits [1]. In particular an 77 
estimated 8.4% of NCD deaths were attributable to either a diet low in fruit or a diet low in 78 
vegetables. Of all NCD deaths attributable to dietary risks, 80.5% were related to 79 
cardiovascular disease (CVD).  80 
Beneficial effects of a diet rich in fruits and vegetables have partly been attributed to 81 
flavonoids, a class of polyphenolic compounds found in plant-based foods and beverages [2]. 82 
Six main flavonoid subclasses have been defined: flavonols, flavan-3ols (including 83 
proanthocyanidins), flavones, flavanones, anthocyanidins and isoflavones. There are at least 84 
300 different flavonoid compounds commonly consumed in the human diet. However, most 85 
of our total flavonoid intake is derived from fewer than 30 flavonoid compounds. The 86 
bioactivity of these compounds and their circulating metabolites differ [3], meaning it is 87 
likely that not all flavonoids will have the same impact on health outcomes [4, 5]. Several 88 
cohort studies have reported an inverse association between high flavonoid intakes and all-89 
cause mortality [6], CVD-related mortality, and coronary heart disease (CHD)-related 90 
mortality [7]. These results are supported by short-term randomised controlled trials 91 
demonstrating that flavonoids and flavonoid-rich foods and beverages positively influence 92 
measures related to the development and progression of CVD [8-10]. Whilst such studies 93 
support a protective effect of a flavonoid rich diet,  none have yet examined whether or not 94 
these effects are consistent amongst individuals with and without unhealthy lifestyle 95 




risk of mortality [1]. Thus, the potential for a moderating impact of such behaviours on the 97 
beneficial effects of a flavonoid-rich diet is unknown. 98 
Therefore, the primary aim of this study was to investigate the associations between intakes 99 
of total flavonoids, flavonoid subclasses and major individual flavonoid compounds, as well 100 
as flavonoid-rich wholefoods and beverages and all-cause mortality in a cohort of older 101 
Australians. Secondary aims were to investigate associations with CVD- and CHD-related 102 
mortality and to explore whether these associations are modified in the presence of risk 103 
factors for early mortality. 104 
 105 
SUBJECTS AND METHODS: 106 
Study Population  107 
This was a prospective cohort study, conducted using data from the Blue Mountains Eye 108 
Study (BMES). Details of the BMES methods have been previously reported [11, 12]. 109 
Briefly, the BMES was the first large population-based assessment of visual impairment and 110 
common eye diseases, conducted in a representative older Australian community. The study 111 
recruited participants within a geographically defined area, in the Blue Mountains region of 112 
New South Wales (postcodes 2780 and 2782). The study population was representative of the 113 
Australian population demographically and for socio-economic status (SES), although they 114 
were slightly older on average [12]. All permanent, non-institutionalised residents, aged 49-115 
97 years, identified in a door-to-door census, were invited to participate. Of the 4433 eligible 116 
residents, 3654 (82.4%) participated in baseline examinations during 1992–1994. Starting in 117 




Western Sydney Area Human Research Ethics Committee and was conducted in adherence to 119 
the tenets of the Declaration of Helsinki. 120 
Participants who did not complete a food frequency questionnaire (FFQ) at baseline (n=756) 121 
and those with implausible energy intakes [<2,092 kJ/day (<500kcal/day) and >14,644 kJ/day 122 
(>3,500kcal/day)] (n=38) were excluded from the analysis. All participants with a history of 123 
diabetes (n=160) or major CVD (acute myocardial infarction or stroke, n=351) at baseline 124 
were excluded from the analysis (Figure 1). The participants provided their previous medical 125 
history and current medications verified by their General Practitioner. These data were coded 126 
using the International Classification of Primary Care-Plus method. This coding methodology 127 
allows aggregation of different terms for similar pathologic entities as defined by the 128 
International Classification of Disease (ICD-10) coding system. These data were used to 129 
determine the presence of pre-existing diabetes, major CVD and/or stroke. 130 
Dietary Assessment  131 
Dietary data were collected using a 145-item self-administered semi-quantitative FFQ, 132 
modified for the Australian diet and vernacular from an early FFQ by Willett et al. [13]. 133 
Respondents were asked to indicate their usual frequency of consuming food items during the 134 
past year, using a nine-category frequency scale that ranged from never to four or more times 135 
per day. Each food was presented on the FFQ with a standard portion size. An allowance for 136 
seasonal variation of fruit and vegetables was made by weighting seasonal fruits and 137 
vegetables. The FFQ has been tested for reproducibility and validity in a subsample of the 138 
study population against weighed food records for nutrients and individual food items [14, 139 





Estimates of the flavonoid content of foods in the FFQ and beverage questionnaire were 142 
derived from the US Department of Agriculture (USDA) Database for the Flavonoid Content 143 
of Selected Foods [2], the USDA Database for the Isoflavone Content of Selected Foods [16] 144 
and the USDA Database for the Proanthocyanidin Content of Selected Foods [17]. The 145 
method of estimating the flavonoid content of foods was similar to that outlined by Mink et 146 
al. [18]. For each food we estimated the intake of each individual flavonoid compound 147 
present. The total intake of each class of flavonoids was then calculated by summing each 148 
individual flavonoid compound within that flavonoid class. Total flavonoid intake was 149 
calculated by summing each of the flavonoid classes. The flavan-3-ol content of foods was 150 
considered to represent the average of total flavan-3-ol and proanthocyanidin monomer 151 
contents. For foods where only the flavan-3-ol or proanthocyanidin monomer content was 152 
available, the single value provided was used to represent the flavan-3-ol content. The 153 
proanthocyanidin content of foods was calculated by summing the proanthocyanidin dimers, 154 
trimers, 4–6mers, 7–10mers and polymers. Where multiple varieties of a food listed in the 155 
FFQ were reported in the databases, the average flavonoid content of all similar varieties was 156 
computed, consistent with the descriptors used in the FFQ output. Foods in the FFQ that were 157 
not in the flavonoid databases were assumed to contain no flavonoids. Intakes of flavonoid 158 
classes (in mg/d) were calculated by multiplying the estimated intake (g edible portion/d) 159 
from the FFQ and beverage questionnaire, with the flavonoid class content (mg/g edible 160 
portion) of each food item on the questionnaire. Estimations for some of the food items were 161 
made using generic recipes found online.  162 
Study outcomes 163 
The primary outcome of this study was death from any cause. Cause of death data were 164 




by matching cause of death codes for CHD and stroke (see below) to the codes recorded in 166 
the NDI up until 31 December 2007 (i.e., 14 years of follow up). Those who were unable to 167 
be matched to the NDI (5%) were excluded from the analysis. Causes of death in the NDI 168 
were defined using the 9th revision of International Classification of Diseases Code (ICD-9) 169 
and International Statistical Classification of Diseases, 10th revision (ICD-10), with the 170 
following codes used for CHD: (ICD-9:410.0 to 410.9, 411.0 to 411.8, 412.0, 414.0 to 414.9 171 
and ICD-10:I21.0 to I21.9, I22.0 to I22.9, I23.0 to I23.8, I24.0 to I24.9 and I25.0 to I25.9) or 172 
stroke: (ICD-9:430.0 to 438.9 and ICD-10:I60.0 to I69.9). The data from the Australian NDI 173 
have been validated, and reported to be highly sensitive and specific for CVD mortality 174 
(92.5% and 89.6%, respectively) [38]. Over 14 years of follow-up there were 677 deaths with 175 
548 recorded cases for CVD mortality in this cohort: 432 for CHD; 176 for stroke; and 60 for 176 
both CHD and stroke as the co-primary causes of death.  177 
Covariates 178 
A physical examination and detailed questionnaires administered by trained interviewers [19, 179 
20], were used to determine values for potential confounding variables including age, gender, 180 
BMI, energy intake, physical activity, hypertension, hypercholesterolemia, smoking status 181 
and SES. Weight was assessed using digital scales with participants wearing light clothes and 182 
no shoes. Height was assessed using a stadiometer and BMI was calculated in kg/m2 at 183 
baseline. Smoking status was determined using categories of never smoked, past smoker and 184 
current smoker; participants were classified as a current smoker if they had  stopped smoking 185 
within the past 12 months [20]. Systolic and diastolic blood pressures were measured with the 186 
participants seated for at least 5 minutes using a mercury sphygmomanometer. Participants 187 
were deemed hypertensive if they were currently taking blood pressure-lowering medication 188 




medication (statins) or had a total cholesterol ≥ 5.5 mmol/L, they were considered 190 
hypercholesteremic. Total cholesterol levels were measured using fasting blood samples [21]. 191 
Use of blood pressure-lowering medication and cholesterol-lowering medication (statins) 192 
were obtained from self-report and were verified by participants’ General Practitioners. 193 
Participants were asked questions regarding walking exercise and the performance of 194 
moderate or vigorous activities, as detailed elsewhere [22]. These data were categorized as 195 
follows: 1) No physical activity; 2) No vigorous physical activity; 3) Vigorous physical 196 
activity. We used home/unit owner (yes/no) as a proxy for SES. Potential dietary 197 
confounding variables were calculated from the FFQ described above.  198 
Statistical Analysis 199 
An analytical protocol was developed prior to the commencement of analysis. Descriptive 200 
data are presented as mean ± SD for normally distributed continuous variables, median (IQR) 201 
for non-normally distributed continuous variables and as number (n) and percentage (%) for 202 
categorical variables. The exposure variables were categorized by tertiles of intake [T1: 0-203 
33.3%; T2: 33.4-66.6%; T3: 66.7-100%]. Cox proportional hazard ratios (HR) and 95% 204 
confidence intervals (CIs) for all-cause, CVD- and CHD-related mortality were computed 205 
using tertiles of the exposure variables, where the lowest tertile (reflecting the lowest intakes) 206 
was the referent category. Schoenfeld residuals were used to check the Cox proportional 207 
hazards assumptions, with no evidence of violation for all outcomes. For all analyses, two 208 
models were fit: 1) minimally-adjusted (age and gender) and 2) multivariable-adjusted (age, 209 
gender, BMI, physical activity, alcohol intake, smoking status, SES, hypercholesterolemia 210 
and hypertension). Given the aetiological focus of our research hypotheses, deaths from non-211 
CVD causes were censored rather than being treated as competing risks [23]. We tested for 212 




continuous, excluding individuals with intakes more than 4 SD’s above the mean for each 214 
exposure. The test of nonlinearity used analysis of variance to compare the model with only 215 
the linear term to the model that included both the linear and the cubic spline terms. To 216 
account for the possibility of reverse causality bias, we repeated all analyses after excluding 217 
all events that occurred within the first 2 years. We tested for effect modification by gender 218 
and age; interaction terms between flavonoid intakes and each of these factors were added to 219 
the models and likelihood ratio chi-square tests were used to formally test for statistical 220 
interaction. To test for potential modification by lifestyle behaviour pattern, we performed a 221 
stratified analysis according to an a priori–defined risk of early mortality characterized by at 222 
least one of the following risk factors: current smoking, alcohol intake >14 standard 223 
drinks/week, BMI ≥ 30 kg/m2 or no physical activity. Hazard ratios were obtained from 224 
models including the two main effects and the interaction term. As flavonoid intake is not 225 
highly correlated with total energy intake, and we believe crude values to be more relevant 226 
than energy-adjusted values, we did not include total energy intake as a covariate in model 1 227 
or 2. Energy intake was however added to model 2 in a sensitivity analysis to assess its effect 228 
on the primary outcome. In two additional sensitivity analyses, we separately added potential 229 
dietary confounders (fibre, saturated fat, polyunsaturated fat, dietary cholesterol and vitamin 230 
C) and a diet quality index to model 2. This diet quality index  has been described elsewhere 231 
[24]. Analyses were undertaken using IBM SPSS® Statistics version 21 (2012, Armonk, NY: 232 
IBM Corp), STATA/IC 14.2 (StataCorp LLC) and R statistics (R Core Team (2016). URL 233 
http://www.R-project.org/.). Statistical significance was set at p≤0.05 (two-tailed) for all tests.   234 
 235 
RESULTS: 236 




In this older Australian population (n=2 349), total flavonoid intake was normally distributed 238 
with a mean of 861.9 mg/d and a SD of 467.5 mg/d. The mean age ± SD was 64.7 ± 9.2 239 
years. The baseline characteristics of the study population overall, and stratified by total 240 
flavonoid intake tertiles [T1 (8.8 - 599.9 mg/d); T2 (600 - 1105.9 mg/d); T3 (1106 - 1969 241 
mg/d)], are shown in Table 1. Participants in the highest tertile of flavonoid intake were less 242 
likely to be current or past smokers, were more likely to be hypertensive and had the lowest 243 
intake of alcohol. Intakes of all dietary characteristics, including total energy, increased 244 
across flavonoid tertiles.  245 
Flavonoid intake 246 
Mean intakes of each flavonoid subclass, the primary flavonoid compounds within each 247 
subclass, and the top three dietary contributors to each subclass are presented in Table 2. 248 
Pearson correlations between flavonoid subclasses varied from weak (r = -0.03 for 249 
isoflavones and flavonols) to high (r = 0.97 for flavonols and total flavonoids). In this 250 
population, flavan-3-ols were the greatest contributors to total flavonoid intake, with 96.9% 251 
of flavan-3-ols in the diet coming from tea. Of those who drank at least one cup of tea per 252 
week (82.0 %), flavan-3-ols accounted for approximately 77.2 % of total flavonoid intake. 253 
The second highest contributors to total flavonoid intake were the proanthocyanidins, coming 254 
primarily from apples and pears, followed by the flavanones, coming mainly from oranges, 255 
orange juice and grapefruit and the flavonols, from tea. The flavonoid subclasses with the 256 
lowest mean intakes were the anthocyanidins, coming predominantly from red wine and port, 257 
the isoflavones, of which soybean intake contributed the most and lastly the flavones, found 258 
mainly in oranges. 259 




During 28 608 person-years of follow-up, 677 out of 2 349 persons (28.8%) died from any 261 
cause. Minimal- and multivariable-adjusted associations of total flavonoid and flavonoid 262 
subclass intakes with all-cause mortality are shown in Table 3. There was a significant linear 263 
trend for a lower risk of all-cause mortality across intake tertiles for the flavone, flavanone, 264 
anthocyanidin and proanthocyanidins subclasses (p for trend <0.05), but only that for the 265 
anthocyanidin subclass remained significant after multivariable adjustment (p for trend = 266 
0.003). For total flavonoid, flavonol and flavan-3-ol intakes, those in the second tertile were 267 
at the lowest risk of death from any cause. In the multivariable-adjusted models, the highest 268 
tertile of anthocyanidin intake was associated with a significantly lower risk of all-cause 269 
mortality (HR: 0.76; 95% CI: 0.61, 0.94), compared to the lowest tertile. The associations 270 
between flavonoid intakes and death due to CVD and CHD are provided in Supplemental 271 
Tables 1 and 2 under “Supplemental data” in the online issue. No significant associations 272 
with any flavonoid subclasses were seen after adjustments were made for potential 273 
confounders.  274 
There was evidence that the relationship between flavonoid intake and all-cause mortality 275 
was non-linear (Table 3) with the greatest hazard reductions seen in the second tertile for 276 
many of the flavonoid subclasses. Therefore, restricted cubic spline curves for the 277 
multivariable adjusted models were generated (Figure 2). The relationships between 278 
flavonoid intake and all-cause mortality seen in Figure 2, support the interpretation of Table 279 
3, which suggests possible threshold associations. For total flavonoid intake, and intakes of 280 
flavonols, flavan-3-ols, flavanones and isoflavones, participants consuming less than the 281 
median intake in tertile 1, had a trend of increased hazard of death from any cause.  282 




Associations between individual foods, contributing to greater than 20% of the intake of any 284 
flavonoid subclass (Table 2), and all-cause mortality are presented in Table 4. In the 285 
minimally-adjusted models, participants in the highest intake tertile had a significantly lower 286 
hazard of mortality for tea, apple and pear, orange and red wine intakes when compared to 287 
those in the lowest intake tertile. These relationships were attenuated in the fully-adjusted 288 
models. For orange juice and grapefruit intakes, those in the second tertile appeared to be at 289 
the lowest risk of dying from any cause.  290 
In accordance with the flavonoid subclass results, multivariable-adjusted cubic splines 291 
(Supplemental Figure 1) illustrate a threshold rather than a dose-response effect for 292 
flavonoid-rich wholefoods. 293 
Associations between individual flavonoid compounds and all-cause mortality 294 
We only examined the relationship of individual flavonoid compounds with mean intakes 295 
>10 mg/day from sources other than tea with all-cause mortality (Table 5). Several 296 
individual flavonoid compounds are found almost exclusively in tea, and thus their 297 
relationship with all-cause mortality will be a proxy for tea intake. In the minimally-adjusted 298 
models, participants in the third tertile for epicatechin, catechin, malvidin and naringenin had 299 
a significantly lower risk of all-cause mortality. For quercetin and hesperetin intakes, the 300 
greatest risk reductions were seen for participants in the second tertile. These relationships 301 
were weakened in the fully-adjusted models. Fully-adjusted spline curves for the relationship 302 
between all-cause mortality and major flavonoid compounds are presented in Supplemental 303 
Figure 2.  304 




No effect modification by age or gender was observed for total flavonoids or any flavonoid 306 
subclass (p-interaction >0.1). The associations of total flavonoid and flavonoid subclass 307 
intakes with all-cause mortality, stratified by risk of early mortality, are shown in Table 6. 308 
The protective effect of total flavonoids, flavonols, flavan-3-ols and proanthocyanidins was 309 
limited to those participants with at least one risk factor (p for interaction <0.05). The risk of 310 
all-cause mortality for flavone, flavanone and anthocyanidin intakes did not differ 311 
significantly between the two groups. The associations of flavonoid-rich foods and intakes of 312 
individual flavonoid compounds with all-cause mortality, stratified by risk of early mortality, 313 
are shown in Supplementary Tables 3 and 4. The reduced risk associated with higher 314 
intakes of apples, tea, quercetin and epicatechin was also limited to those participants in the 315 
‘at risk’ group (p for interaction <0.05). 316 
Sensitivity analyses 317 
Including energy intake in model 2 did not change the estimates. Adjusting for other dietary 318 
confounders such as fibre, saturated fat, polyunsaturated fat, dietary cholesterol and vitamin 319 
C or a diet quality index did not change the outcomes materially. Excluding participants who 320 
died within the first two years (n=59), to account for reverse causality bias, slightly 321 
strengthened the relationship between total and individual flavonoid subclass intake and all-322 
cause mortality.  323 
 324 
DISCUSSION 325 
With almost 20% of NCD-related deaths and 42.3% of CVD deaths in Australia attributable 326 
to dietary risk factors [1], identifying optimal dietary patterns for disease prevention is 327 




a reduced risk of all-cause mortality with moderate to high intakes of flavonoids and 329 
flavonoid-rich foods. Our results indicate that these effects plateau and that the greatest risk 330 
reduction is seen when moving from a low to a moderate intake. We also demonstrate for the 331 
first time that the inverse association between total flavonoid intake and all-cause mortality 332 
was mostly apparent in participants with at least one risk factor for early mortality. 333 
In this cohort, approximately 74% of total flavonoid intake was attributed to the flavan-3-ol 334 
subclass and 15% came from the proanthocyanidin subclass, where tea and apples were the 335 
major dietary contributors, respectively. Intakes of total flavonoids and of each flavonoid 336 
subclass were comparable to those reported in another Australian prospective cohort study 337 
examining the relationship between flavonoid intake and mortality [25]. In contrast, a 338 
considerably lower total flavonoid intake has been reported in several other studies [6, 26, 27] 339 
most likely explained by the lower intake of tea in these cohorts.  340 
The findings in our study examining the relationship between total flavonoid intake and all-341 
cause mortality are consistent with other studies [18, 26-31]. Although there were apparent 342 
risk reductions, they generally no longer remained significant after adjusting for potential 343 
confounders. In a meta-analysis of eight studies, participants in the highest versus the lowest 344 
category of total flavonoid intake had an 18% lower risk of all-cause mortality (RR: 0.82; 345 
95% CI: 0.72–0.92) [7]. However, we and others have shown that the greatest risk reduction 346 
is often seen in the moderate flavonoid intake groups [18, 27-29, 31]. Of these eight studies, 347 
only one study demonstrated a significantly lower risk of all-cause mortality with high 348 
compared to low flavonoid intake (HR: 0.38; 95% CI: 0.22–0.64) [6]. While there are several 349 
key differences in study design, dietary assessment, and participant characteristics between 350 
these prospective cohort studies, the age of the participants at baseline (80 ± 3 years) and the 351 




large risk reduction was observed as the population would have been at a very high risk of 353 
mortality. Similar non-significant reductions in CVD-related mortality risk with moderate to 354 
high flavonoid consumption have been demonstrated in the present study and others [18, 26].  355 
Several studies have examined the relationship between individual flavonoid subclass intakes 356 
and all-cause mortality [18, 26-29]. However, results are too inconsistent to suggest that one 357 
flavonoid subclass may be more beneficial than another. In the present study, after adjusting 358 
for potential confounders, the anthocyanidin subclass was associated with the lowest risk of 359 
all-cause mortality while Ivey et al. showed that a high intake of the flavan-3-ol subclass was 360 
associated with the lowest risk [28]. For individual flavonoid compounds we show that after 361 
adjusting for potential confounders only high intakes of malvidin and moderate intakes of 362 
epicatechin were significantly associated with a lower risk of mortality. However, there was a 363 
trend for a lower risk with moderate intakes of quercetin and hesperetin and moderate to high 364 
intakes of naringenin. To date, only one other study [30] has examined the relationship 365 
between individual flavonoid compounds and all-cause mortality; Knekt et al., demonstrated 366 
non-significant lower risks in all-cause mortality for quercetin, kaempferol, hesperetin and 367 
naringenin.  368 
To our knowledge, this is the first observational study to provide evidence that the protective 369 
effects of flavonoids may be confined to populations with unhealthy lifestyle habits placing 370 
them at an increased risk of early mortality. Cigarette smoking [32], obesity [33], high 371 
alcohol consumption (>2 standard drinks per day) [34] and physical inactivity [35] have been 372 
shown to have harmful effects on nitric oxide bioavailability, endothelial function, blood 373 
pressure, inflammation, blood lipids, platelet function and thrombosis, while strong evidence 374 
suggests that flavonoids can ameliorate these intermediate risk factors for CVD [36-40]. We 375 




with a significantly lower risk of all-cause mortality in participants with at least one risk 377 
factor while little or no benefit was seen in participants with none of these risk factors. 378 
Consistent findings were observed with flavonoid-rich foods (apples and tea) and individual 379 
flavonoid compounds (quercetin and epicatechin). This finding may partly explain why we 380 
and others have shown only non-significant reductions in risk of all-cause mortality with 381 
moderate to high flavonoid consumption. Analyzing this relationship in the entire study 382 
population may have diluted the protective effect afforded by flavonoids to those at a higher 383 
risk. That anthocyanidin intake was associated with a reduced risk in both the ‘at risk’ and 384 
‘not at risk’ subgroups explains why this was the only flavonoid subclass associated with a 385 
significantly lower risk of all-cause mortality in the whole study population. This finding 386 
warrants further investigation in both observational studies and clinical trials. Additionally, 387 
future clinical trials investigating the mechanisms behind the beneficial effects of flavonoids 388 
should be conducted in cohorts at risk for CVD, where the potential for improvement might 389 
be greater.  390 
In the present study, our analyses suggest possible threshold levels for intakes of total 391 
flavonoid, flavonoid subclass, individual flavonoid compounds and flavonoid-rich wholefoods, 392 
rather than a dose response effect. Due to the observational nature of the study, we are not able 393 
to infer causality or rule out residual or unmeasured confounding. Although adjusting for 394 
dietary confounders such as fibre, saturated fat, polyunsaturated fat, dietary cholesterol and 395 
vitamin C did not change the outcomes materially, the possibility of flavonoids being a marker 396 
of other potentially protective unobserved dietary factors cannot be discounted. However, 397 
benefits of flavonoids and flavonoid-rich foods were independent of overall diet quality as 398 
associations were unchanged after adjustments for a healthy eating index. Additionally, 399 




potentially different modifying effects. For this study we only used baseline dietary intake and 401 
covariate data; it is possible that intakes may have changed over the 14 years of follow-up, 402 
resulting in some non-differential misclassification of the exposures attenuating the power to 403 
detect an association. A second FFQ was completed after 5 years of follow-up; out of 1480 404 
participants who completed both FFQ’s, 64% stayed in the same tertile for total flavonoid 405 
intake, 15.5% increased their total flavonoid intake and total 19.7% decreased their flavonoid 406 
intake. It should also be noted that the estimation of flavonoid intake was based on a US 407 
database, meaning that regional variation in the flavonoid content of foods could not be 408 
accounted for in this study. 409 
In this prospective cohort study, we demonstrate that a moderate to high intake of flavonoids 410 
is protective against mortality in elderly Australians at an increased risk of early mortality. This 411 
protective effect was not observed in participants without these risk factors. Results also 412 
indicate threshold levels for which benefits are seen.  413 
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n = 2349 
Total flavonoid intake tertiles 
1 
n = 783 
2 
n = 783 
3 
n = 783 




286 [157.6 – 
421.4] 




Sociodemographic characteristics     
Age (years) 64.7 ± 9.2 63.2 ± 9.0 65.7 ± 9.6 65.1 ± 8.9 
Gender (male), n (%) 971 (41.3) 339 (43.3) 327 (41.8) 305 (39.0) 
Body mass index (kg/m2) 26.0 ± 4.4 26.4 ± 4.6 25.9 ± 4.4 25.8 ± 4.1 








































Hypertensive, n (%) 1632 (69.7) 520 (66.7) 542 (69.3) 570 (73.1) 
High cholesterol, n (%) 1578 (72.3) 509 (70.3) 541 (74.6) 528 (71.93) 
SES (home/unit owner), n (%) 2079 (90.3) 664 (86.9) 720 (93.6) 695 (90.3) 
Dietary characteristics     
Energy intake (kcals/day, ×1000)  2.1 ± 0.6 1.9 ± 0.6 2.1 ± 0.6 2.2 ± 0.6 
Alcohol (drinks/week) 1.8 [0 – 10.5] 2.3 [0 – 10.5] 2.3 [0 – 10.5] 0.8 [0 – 8.3] 
 
 
Dietary fibre (g/d) 27.3 ± 10.5 25.0 ± 9.7 28.0 ± 10.4 28.9 ± 11.0 
Protein (g/d) 87.1 ± 27.1 81.7 ± 28.3 87.6 ± 25.9 91.8 ± 26.2 
Carbohydrate (g/d) 233.1 ± 75.5 212.1 ± 74.6 235.9 ± 71.1 251.4 ± 75.7 
Saturated fat (g/d) 29.6 ± 13.0 27.7 ± 13.1 29.5 ± 12.1 31.5 ± 13.5 
Polyunsaturated fat (g/d) 12.5 ± 5.4 11.7 ± 5.4 12.6 ± 5.4 13.2 ± 5.2 
Vitamin C (mg/d)* 182.5 ± 95.0 172.2 ± 87.7 186.1 ± 96.8 189.3 ± 99.4 






304.8 ± 138.6 
Data expressed as mean ± SD unless otherwise stated.   
*Vitamin C without dietary supplementation 





Table 2. Flavonoid intake in study population  
Flavonoid class Respective compounds* 
Top three dietary contributors 
(percentage contribution to class 
intake) 











Tea (96.9%); apples and pears 
(1.0%); bananas (0.6%) 
641.0 ± 426.1 
Proanthocyanidins Monomers; dimers; trimers; 
4–6mers; 7–10mers; 
polymers 
Apples and pears (42.8%); tea 
(15.0%); plums (6.0%) 
134.2 ± 90.8 
Flavanones Hesperetin; Naringenin; 
Eriodictyol 
Orange (46.8%); orange juice 
(26.1%); grapefruit (21.0%) 
34.5 ± 37.6 
Flavonols Quercetin; Kaempferol; 
Myricetin; Isorhamnetin: 
Tea (68.8%); apples and pears 
(6.8%); beer (2.9%) 
32.6 ± 15.7 
Anthocyanidins Malvidin; Cyanidin 
Delphinidin; Petunidin; 
Peonidin; Pelargonidin 
Red wine (56.8%); port (18.7%); 
apples and pears (8.9%) 
17.1 ± 37.2 
Isoflavones Genistein; Daidzein; 
Glycitein  
Soybeans (24.8%); white bread 
(14.9%); coffee (12.9%) 
1.3 ± 1.6 
 
 
Flavones Luteolin; Apigenin Orange (42.2%); meat and vegetable 
soup (12.2%); green peas (10.3%) 
1.2 ± 0.8 
*In descending order of mean intake 





Table 3. Hazard ratios of all-cause mortality by tertiles of flavonoid intake  




1 2 3 
Total Flavonoids     
    No. deaths (%) 220 (28.1) 233 (29.8) 224 (31.2)  
    Intake (mg/d)* 286.1 (8.8 – 599.9) 915.2 (600 – 1105.9) 1372.1 (1106 – 1969)  
    HR (95% CI)     
        Model 1 1.00 0.81 (0.67, 0.97) 0.90 (0.75, 1.09) 0.0059 
        Model 2 1.00 0.88 (0.72, 1.08) 0.98 (0.80, 1.20) 0.0343 
Flavonols     
    No. deaths 217 (27.7) 229 (29.2) 231 (29.5)  
    Intake (mg/d)* 13.4 (1.7 – 25.0) 34.4 (25.0 – 42.3) 49.4 (42.3 – 84.8)  
    HR (95% CI)     
        Model 1 1.00 0.81 (0.67, 0.97) 0.93 (0.77, 1.12) 0.0896 
        Model 2 1.00 0.85 (0.69, 1.04) 0.98 (0.80, 1.20) 0.2418 
Flavones      
    No. deaths (%) 247 (31.5) 209 (26.7) 221 (28.2)  
    Intake (mg/d)* 0.44 (0.02 – 0.72) 1.02 (0.72 – 1.32) 1.77 (1.32 – 7.70)  
    HR (95% CI)     
        Model 1 1.00 0.86 (0.71, 1.03) 0.75 (0.62, 0.90) 0.1199 
        Model 2 1.00 0.90 (0.74, 1.10) 0.83 (0.68, 1.02) 0.4691 
Flavan-3-ols     
    No. deaths (%) 224 (28.6) 231 (29.5) 222 (28.4)  
    Intake (mg/d)* 49.1 (1.3 – 310.5) 729.7 (310.6 – 747.6) 1158.0 (747.9 – 1224.0)  
    HR (95% CI)     
        Model 1 1.00 0.76 (0.63, 0.91) 0.86 (0.71, 1.03) 0.0270 
        Model 2 1.00 0.82 (0.67, 1.01) 0.92 (0.75, 1.13) 0.0725 
Flavanones     
 
 
    No. deaths (%) 243 (31.0) 216 (27.6) 218 (27.8)  
    Intake (mg/d)* 4.3 (0.05 – 10.3) 24.8 (10.3 – 38.9) 64.3 (38.9 – 548.9)  
    HR (95% CI)     
        Model 1 1.00 0.86 (0.72, 1.04) 0.79 (0.66, 0.94) 0.0192 
        Model 2 1.00 0.91 (0.75, 1.11) 0.91 (0.75, 1.16) 0.1243 
Isoflavones     
    No. deaths (%) 239 (30.7) 224 (28.6) 214 (27.3)  
    Intake (mg/d)* 0.60 (0.01 – 0.81) 0.99 (0.82 – 1.22) 1.61 (1.23 – 29.89)  
    HR (95% CI)     
        Model 1 1.00 0.96 (0.80, 1.15) 0.98 (0.81, 1.18) 0.0630 
        Model 2 1.00 0.97 (0.79, 1.18) 0.99 (0.81, 1.21) 0.1482 
Anthocyanidins     
    No. deaths (%) 258 (33.0) 234 (29.9) 185 (23.6)  
    Intake (mg/d)* 2.1 (0.0 – 3.8) 5.6 (3.9 – 9.2) 21.3 (9.2 – 333.7)  
    HR (95% CI)     
        Model 1 1.00 0.89 (0.74, 1.06) 0.66 (0.55, 0.80) <0.0001 
        Model 2 1.00 1.04 (0.85, 1.26) 0.76 (0.61, 0.94) 0.0015 
Proanthocyanidins     
    No. deaths (%) 250 (31.9) 227 (29.0) 200 (25.5)  
    Intake (mg/d)* 53.8 (0.2 – 85.9) 116.7 (86.0 – 155.4) 200.4 (155.5 – 747.8)  
    HR (95% CI)     
        Model 1 1.00 0.88 (0.74, 1.05) 0.71 (0.59, 0.85) 0.0999 
        Model 2 1.00 1.01 (0.83, 1.23) 0.86 (0.70, 1.05) 0.4308 
Hazard ratios (95% CI) for 14-year all-cause mortality analysed using multivariate Cox proportional hazard models.  
Model 1 was adjusted for age and gender and model 2 was adjusted for age, gender, BMI, smoking status, physical 
activity, alcohol intake, hypertension, hypercholesterolemia and social economic status. 
*Median; range in parentheses (all such values). #Tests for nonlinearity used analysis of variance to compare the model 
with only the linear term to the model that includes both the linear and the cubic spline terms. 
 
 
Table 4. Hazard ratios of all-cause mortality by tertiles of flavonoid-rich foods  




1 2 3 
Tea     
    No. deaths (%) 129 (28.0) 110 (27.4) 438 (29.5)  
    Intake (ml/d)* 0 (0-35) 250 (108-250) 625 (625-1000)  
    HR (95% CI)     
        Model 1 1.00 0.80 (0.62, 1.03) 0.77 (0.63, 0.94) 0.0276 
        Model 2 1.00 0.84 (0.63, 1.10) 0.84 (0.68, 1.05) 0.0770 
Apples and pears     
    No. deaths (%) 279 (32.4) 222 (28.0) 176 (25.3)  
    Intake (mg/d)* 10.5 (1 – 21.1) 64.7 (64.7 – 118.9) 150.5 (150.5 – 602)  
    HR (95% CI)     
        Model 1 1.00 0.89 (0.74, 1.06) 0.70 (0.58, 0.85) 0.1800 
        Model 2 1.00 1.02 (0.84, 1.23) 0.83 (0.68, 1.03) 0.4240 
Oranges     
    No. deaths (%) 301 (50.8) 186 (26.2) 190 (28.0)  
    Intake (mg/d)* 2.5 (0 – 8.8) 53.8 (17.5 – 53.8) 125.0 (98.8 – 500)  
    HR (95% CI)     
        Model 1 1.00 0.83 (0.69, 0.99) 0.75 (0.62, 0.90) 0.0416 
        Model 2 1.00 0.87 (0.72, 1.06) 0.83 (0.68, 1.02) 0.1188 
Orange juice     
    No. deaths (%) 312 (31.9) 183 (22.3) 182 (33.1)  
    Intake (ml/d)* 2.5 (0 – 2.5) 17.5 (8.8 – 53.8) 125 (98.8 – 500)  
    HR (95% CI)     
        Model 1 1.00 0.79 (0.66, 0.95) 1.00 (0.84, 1.21) 0.0198 
        Model 2 1.00 0.80 (0.65, 0.97) 1.05 (0.87, 1.28) 0.0251 
Red wine     
 
 
    No. deaths (%) 445 (31.5) 116 (27.0) 116 (22.8)  
    Intake (ml/d)* 0 (0 – 0) 2.4 (2.4 – 2.4) 16.8 (8.4 – 480)  
    HR (95% CI)     
        Model 1 1.00 0.90 (0.73, 1.10) 0.77 (0.63, 0.95) <0.0001 
        Model 2 1.00 0.91 (0.73, 1.14) 0.79 (0.62, 1.00) 0.0027 
Grapefruit     
    No. deaths (%) 434 (33.0) 114 (22.4) 129 (24.7)  
    Intake (mg/d)* 0 (0 – 0) 2.7 (2.7 – 2.7) 18.6 (9.3 – 532)  
    HR (95% CI)     
        Model 1 1.00 0.69 (0.56, 0.85) 0.74 (0.60, 0.90) 0.0221 
        Model 2 1.00 0.79 (0.63, 0.99) 0.81 (0.66, 1.00) 0.1668 
Hazard ratios (95% CI) for 14-year all-cause mortality analysed using multivariate Cox proportional hazard models.  
Model 1 was adjusted for age and gender and model 2 was adjusted for age, gender, BMI, smoking status, physical 
activity, alcohol intake, hypertension, hypercholesterolemia and social economic status. 
*Median; range in parentheses (all such values). #Tests for nonlinearity used analysis of variance to compare the model 
with only the linear term to the model that includes both the linear and the cubic spline terms. 
 
 
Table 5. Hazard ratios of all-cause mortality by tertiles of individual flavonoid compound intake  




1 2 3 
Quercetin     
    No. deaths (%) 224 (28.6) 227 (29.0) 226 (28.9)  
    Intake (mg/d)* 9.00 (1.33 – 15.83) 20.76 (15.84 – 25.16) 29.14 (25.17 – 54.81)  
    HR (95% CI)     
        Model 1 1.00 0.82 (0.68, 0.98) 0.86 (0.72, 1.04) 0.1191 
        Model 2 1.00 0.85 (0.69, 1.04) 0.96 (0.78, 1.17) 0.2001 
Epicatechin     
    No. deaths (%) 239 (30.6) 228 (29.1) 210 (26.9)  
    Intake (mg/d)* 9.60 (0.59 – 16.10) 21.40 (16.11 – 25.21) 30.83 (25.22 – 66.42)  
    HR (95% CI)     
        Model 1 1.00 0.80 (0.66, 0.96) 0.75 (0.62, 0.90) 0.0148 
        Model 2 1.00 0.80 (0.66, 0.98) 0.86 (0.70, 1.05) 0.0340 
Catechin     
    No. deaths (%) 221 (28.3) 245 (31.3) 211 (27.0)  
    Intake (mg/d)* 9.06 (0.20 – 13.46) 17.06 (13.47 – 20.22) 24.33 (20.23 – 57.22)  
    HR (95% CI)     
        Model 1 1.00 0.96 (0.80, 1.15) 0.80 (0.67, 0.97) 0.0048 
        Model 2 1.00 1.00 (0.82, 1.23) 0.90 (0.73, 1.10) 0.0527 
Malvidin     
    No. deaths (%) 254 (32.4) 231 (29.6) 192 (24.6)  
    Intake (mg/d)* 0.08 (0 – 0.44) 1.34 (0.45 – 2.49) 12.73 (251.04)  
    HR (95% CI)     
        Model 1 1.00 0.96 (0.80, 1.14) 0.73 (0.60, 0.88) 0.0015 
        Model 2 1.00 0.98 (0.81, 1.19) 0.75 (0.60, 0.94) 0.0549 
Hesperitin     
 
 
    No. deaths (%) 249 (31.9) 207 (26.5) 221 (28.2)  
    Intake (mg/d)* 2.28 (0 – 5.66) 14.39 (5.67 – 25.60) 37.79 (25.63 – 214.91)  
    HR (95% CI)     
        Model 1 1.00 0.79 (0.65, 0.95) 0.79 (0.66, 0.95) 0.0243 
        Model 2 1.00 0.84 (0.69, 1.03) 0.91 (0.75, 1.11) 0.1295 
Naringenin     
    No. deaths (%) 247 (31.6) 217 (27.7) 213 (27.2)  
    Intake (mg/d)* 1.55 (0 – 3.37) 6.20 (3.38 – 10.39) 17.24 (10.40 – 333.11)  
    HR (95% CI)     
        Model 1 1.00 0.82 (0.68, 0.98) 0.74 (0.62, 0.89) 0.0036 
        Model 2 1.00 0.89 (0.73, 1.08) 0.87 (0.71, 1.07) 0.1301 
Hazard ratios (95% CI) for 14-year all-cause mortality analysed using multivariate Cox proportional hazard models.  
Model 1 was adjusted for age and gender and model 2 was adjusted for age, gender, BMI, smoking status, physical 
activity, alcohol intake, hypertension, hypercholesterolemia and social economic status. 
*Median; range in parentheses (all such values). #Tests for nonlinearity used analysis of variance to compare the model 
with only the linear term to the model that includes both the linear and the cubic spline terms. 
 
 
Table 6. Hazard ratios of total mortality by tertiles of flavonoid intake stratified by risk of early mortality 
 Not ‘at risk’ group 
(n=1 209) 




 Flavonoid intake tertile Flavonoid intake tertile 
 1 2 3 1 2 3  
Total Flavonoids        
    Model 1 1.00 1.02 (0.77, 1.36) 1.15 (0.87, 1.53) 1.00 0.69 (0.54, 0.88) 0.79 (0.61, 1.02) 0.013 
    Model 2 1.00 1.03 (0.76, 1.41) 1.20 (0.89, 1.63) 1.00 0.69 (0.53, 0.89) 0.77 (0.59, 1.00) 0.006 
Flavonols        
    Model 1 1.00 1.07 (0.80, 1.43) 1.18 (0.89, 1.57) 1.00 0.64 (0.50, 0.82) 0.80 (0.63, 1.03) 0.015 
    Model 2 1.00 1.03 (0.76, 1.40) 1.20 (0.89, 1.62) 1.00 0.64 (0.49, 0.83) 0.77 (0.59, 1.01) 0.007 
Flavones        
    Model 1 1.00 0.86 (0.65, 1.14) 0.86 (0.66, 1.12) 1.00 0.91 (0.72, 1.16) 0.75 (0.58, 0.97) 0.238 
    Model 2 1.00 0.90 (0.67, 1.21) 0.82 (0.62, 1.08) 1.00 0.89 (0.69, 1.15) 0.79 (0.61, 1.03) 0.620 
Flavan-3-ols        
    Model 1 1.00 1.00 (0.75, 1.33) 1.08 (0.81, 1.44) 1.00 0.62 (0.49, 0.80) 0.78 (0.61, 1.00) 0.028 
    Model 2 1.00 1.00 (0.74, 1.36) 1.10 (0.81, 1.49) 1.00 0.61 (0.47, 0.80) 0.75 (0.58, 0.98) 0.012 
Flavanones        
    Model 1 1.00 0.86 (0.64, 1.14) 0.87 (0.67, 1.13) 1.00 0.87 (0.68, 1.10) 0.78 (0.60, 1.00) 0.063 
 
 
    Model 2 1.00 0.90 (0.67, 1.22) 0.88 (0.66, 1.17) 1.00 0.88 (0.68, 1.14) 0.81 (0.62, 1.07) 0.160 
Isoflavones        
    Model 1 1.00 0.91 (0.50, 1.65) 1.31 (0.75, 2.31) 1.00 0.97 (0.55, 1.70) 1.13 (0.65, 1.96) 0.247 
    Model 2 1.00 1.02 (0.54, 1.94) 1.31 (0.70, 2.45) 1.00 1.05 (0.56, 1.97) 1.17 (0.64, 2.17) 0.440 
Anthocyanidins        
    Model 1 1.00 0.96 (0.73, 1.25) 0.69 (0.52, 0.92) 1.00 0.91 (0.72, 1.16) 0.69 (0.53, 0.89) 0.191 
    Model 2 1.00 1.03 (0.79, 1.37) 0.71 (0.52, 0.96) 1.00 0.95 (0.73, 1.22) 0.70 (0.54, 0.92) 0.130 
Proanthocyanidins        
    Model 1 1.00 0.95 (0.72, 1.27) 0.89 (0.67, 0.17) 1.00 0.90 (0.71, 1.14) 0.65 (0.49, 0.85) 0.021 
    Model 2 1.00 0.99 (0.73, 1.34) 0.91 (0.68, 1.22) 1.00 0.95 (0.74, 1.22) 0.69 (0.52, 0.92) 0.037 
Hazard ratios (95% CI) for 14-year all-cause mortality analysed using multivariate Cox proportional hazard models.  
Model 1 was adjusted for age and gender and model 2 was adjusted for age, gender, hypertension, hypercholesterolemia and social economic status. 
*Likelihood ratio test was used to calculate the P-value for interaction by comparing the model with the product term between flavonoid intake (continuous) and risk 




Figure 1. Consort flow diagram. AMI, acute myocardial infarction; CHD, coronary heart 
disease; CVD, cardiovascular disease. 
Figure 2. Cubic spline curves for the association between flavonoid intakes (mg/day) and all-
cause mortality among participants of the Blue Mountains Eye Study, adjusted for age, 
gender, BMI, smoking status, physical activity, alcohol intake, hypertension, 
hypercholesterolemia and social economic status. Individuals with intakes > mean+4 SD’s 
were excluded for each subclass (n≤46). 
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